Switzerland’s Galderma today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

Valmet announced on December 18, 2024, that the Board of Directors of Valmet has decided to use the authorization granted by the Annual General Meeting held on March 21, 2024, to repurchase the ...

Rare Cannabinoid Company, a leader in hemp-derived wellness products, is celebrating February Sleep Awareness Month with an exclusive Buy One, Get One 50% Off sale on all CBN ...

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

In December, the FDA approved Nemluvio (nemolizumab) in combination with topical corticosteroids and/or calcineurin inhibitors for the treatment of adults and pediatric patients 12 years of age and ...

Swiss dermatology company Galderma (GALD.SW) today announced today results from its new Phase IIIb RELAX clinical trial demonstrating the rapid onset and the long-lasting duration of aesthetic ...

There are about 75,000 adults in the US living with prurigo nodularis who are in desperate need of new treatment options, according to the two drugmakers. FDA clears Dupixent as first drug for ...

Nemluvio (nemolizumab-ilto) Interleukin-31 receptor antagonist Treatment of adults and pediatric patients 12 years of age and older with moderate to severe atopic dermatitis in combination with ...